Cardinal Health Aktie News

The U.S. Food and Drug Administration on Thursday sent a warning letter to Cardinal Health after an inspection of its facility in Illinois showed that the company was marketing unapproved devices.

Are we headed for a repeat of 2022's brutal selloff? While no one can predict the future with certainty, current market trends are raising some ominous red flags.

Healthcare stocks, especially industry leaders that offer a wide range of products and services, can be an investor's best friend due to the growing need for increased development of healthcare products and services. These stocks tend to provide investors with a substantial return on their investment.

The pharmaceutical distribution contract with OptumRx will expire in June.

Cardinal Health said on Monday its pharma distribution contracts with UnitedHealth Group Inc's OptumRx unit will not be renewed after they expire at the end of June.

Cardinal Health Inc. ‘s stock CAH, +2.07% fell 3.6% early Monday, after the pharmaceuticals distributor and medical lab products maker said its contracts with pharmacy benefits manager OptumRx will expire at the end of June and will not be renewed. The Dublin, Ohio-based company said it still expects 2024 EPS of $7.20 to $7.35 despite the end of the contract, which generated 16% of its revenue ...

DUBLIN, Ohio , April 22, 2024 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its pharmaceutical distribution contracts with OptumRx, which expire at the end of June 2024, will not be renewed. The company reaffirmed its fiscal 2024 non-GAAP diluted EPS guidance of $7.20 to $7.35.

Cardinal Health is overvalued, with a dividend yield lower than its historical average and a high P/E ratio. Growth projections for the Company are moderate, with a projected growth rate of 7.8% for the next 5 years. Return projections using the discounted dividend model suggest that CAH is still overvalued, with a fair price of around $79 compared to its current price of $106.